ArticleDermatology and therapy2026
Effectiveness of Botulinum Toxin Type A for Trichodynia Associated with Hair Loss Disorders: A Retrospective Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTrichodynia significantly impairs quality of life in patients with hair loss, for which effective treatments remain limited. This study evaluates the use of intradermal botulinum toxin type A (BTA) in patients with trichodynia unresponsive to conventional therapies.
methodsWe retrospectively analyzed 21 patients with trichodynia and with alopecia who had discontinued or refused systemic treatments. BTA was administered using the Nappage technique. Symptom severity and disease activity were assessed using the Visual Analogue Scale (VAS) and the Lichen Planopilaris Activity Index (LPPAI), respectively.
resultsMost patients (90.5%) reported symptomatic improvement within 18.3 days on average. Mean VAS scores declined from 8.0 to 2.0 at 3 months and reached 0.0 by 6 months. In cicatricial alopecia, LPPAI scores showed significant reduction. Treatment was well tolerated, with only minor adverse effects. DISCUSSION: The clinical improvement observed may be explained by the neuromodulatory effects of BTA on neurogenic inflammation, including inhibition of substance P and CGRP release. Notably, patients with inflammatory scarring alopecias showed a more pronounced response than those with noncicatricial alopecias, suggesting that BTA may be particularly beneficial in conditions where pain is linked to active perifollicular inflammation.
conclusionsIntradermal BTA appears to be a safe and potentially effective treatment for trichodynia, particularly in patients with scarring alopecia who are not candidates for systemic therapy. These findings warrant further validation in controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.